Table 3.
SMR and AER for all-cause late mortality among 2-year survivors of autologous BMT in childhood
| Variable | Entire cohort, | Number of all-cause deaths | Rate of all-cause death per 1000 person-years | ||||||
|---|---|---|---|---|---|---|---|---|---|
| no. of patients | Observed | Expected | SMR | 95% CI | Observed | Expected | AER | 95% CI | |
| All patients | 345 | 103 | 4.7 | 21.8 | 17.9-26.3 | 20.4 | 0.9 | 19.4 | 15.5-23.4 |
| Sex | |||||||||
| Male | 212 | 53 | 3.9 | 13.8 | 10.4-17.8 | 15.7 | 1.1 | 14.6 | 10.4-18.8 |
| Female | 133 | 50 | 0.9 | 57.9 | 43.3-75.4 | 29.6 | 0.5 | 29.0 | 20.9-37.2 |
| Age at BMT, y | |||||||||
| 0-4 | 97 | 28 | 0.8 | 36.4 | 24.5-51.6 | 19.6 | 0.5 | 19.1 | 11.8-26.3 |
| 5-9 | 57 | 20 | 0.7 | 29.2 | 18.2-43.9 | 20.9 | 0.7 | 20.2 | 11.0-29.3 |
| 10-14 | 55 | 19 | 0.7 | 26.2 | 16.1-39.7 | 24.7 | 0.9 | 23.8 | 12.7-34.9 |
| 15-21 | 136 | 36 | 2.5 | 14.2 | 10.1-19.4 | 18.9 | 1.3 | 17.6 | 11.4-23.7 |
| Year of BMT | |||||||||
| <1990 | 74 | 33 | 1.8 | 18.2 | 12.7-25.2 | 22.8 | 1.3 | 21.5 | 13.8-29.3 |
| 1990-1999 | 129 | 37 | 1.9 | 19.7 | 14.2-26.8 | 16.8 | 0.9 | 15.9 | 10.5-21.3 |
| 2000-2010 | 142 | 33 | 1.0 | 32.0 | 22.3-44.2 | 23.5 | 0.7 | 22.7 | 14.7-30.7 |
| Source of stem cells | |||||||||
| Bone marrow | 163 | 53 | 3.1 | 17.0 | 14.1-24.6 | 17.4 | 1.0 | 16.4 | 11.7-21.4 |
| PBSCs | 181 | 50 | 1.6 | 31.6 | 22.0-39.9 | 25.0 | 0.8 | 24.2 | 17.3-31.1 |
| Primary diagnosis | |||||||||
| ALL | 43 | 21 | 0.9 | 24.0 | 15.2-35.8 | 26.8 | 1.1 | 25.7 | 14.2-37.2 |
| AML | 45 | 6 | 0.9 | 6.8 | 2.7-13.8 | 6.5 | 1.0 | 5.5 | 0.3-10.7 |
| HL | 90 | 23 | 1.5 | 15.2 | 9.8-22.2 | 18.9 | 1.3 | 17.7 | 9.9-25.4 |
| NHL | 31 | 8 | 0.6 | 13.0 | 6.0-24.3 | 15.9 | 1.2 | 14.7 | 3.7-25.7 |
| Neuroblastoma | 79 | 25 | 0.5 | 52.6 | 24.6-76.0 | 24.2 | 0.5 | 23.8 | 14.3-33.3 |
| Other malignant disease* | 57 | 20 | 0.4 | 56.4 | 35.1-84.8 | 33.2 | 0.6 | 32.6 | 18.1-47.2 |
| Disease status at HCT | |||||||||
| Standard risk of relapse† | 133 | 39 | 2.5 | 15.4 | 11.1-20.8 | 17.1 | 1.1 | 16.0 | 10.6-21.4 |
| High risk of relapse | 212 | 64 | 2.2 | 29.2 | 22.6-37.0 | 23.0 | 0.8 | 22.2 | 16.6-27.9 |
| Overall survival after HCT, y | |||||||||
| 2-5 | 65 | 65 | 0.1 | 660.8 | 512.9-834.7 | 319.5 | 0.5 | 319.0 | 241.3-396.7 |
| 6-9 | 73 | 24 | 0.3 | 78.4 | 51.1-114.1 | 41.9 | 0.5 | 41.4 | 24.6-58.1 |
| 10-14 | 45 | 9 | 0.4 | 20.6 | 9.9-37.2 | 15.9 | 0.8 | 15.2 | 4.8-25.5 |
| 15+ | 162 | 5 | 3.9 | 1.3 | 0.5-2.8 | 1.3 | 1.0 | 0.3 | −0.9-1.5 |
*
Includes 25 Ewing sarcomas, 11 Wilms tumor, 9 CNS tumors, 4 desmoplastic small round cell tumors, 6 soft tissue sarcoma, 1 ovarian tumor, 1 hepatoblastoma, and 1 multiple myeloma.
†
Standard risk: first or second complete remission after acute leukemia or lymphoma; all others high risk.